Galmed Pharmaceuticals Ltd.
GLMD
$0.52
-$0.01-1.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 684.00K | 946.00K | 1.01M | 1.05M | 630.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.04M | 3.04M | 2.10M | 2.11M | 1.26M |
| Operating Income | -2.04M | -3.04M | -2.10M | -2.11M | -1.26M |
| Income Before Tax | -1.91M | -4.82M | -1.89M | -2.50M | -1.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.91M | -4.82M | -1.89M | -2.50M | -1.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.91M | -4.82M | -1.89M | -2.50M | -1.10M |
| EBIT | -2.04M | -3.04M | -2.10M | -2.11M | -1.26M |
| EBITDA | -- | -3.02M | -2.07M | -2.09M | -1.24M |
| EPS Basic | -0.29 | -0.80 | -0.35 | -0.63 | -0.62 |
| Normalized Basic EPS | -0.18 | -0.29 | -0.22 | -0.31 | -0.39 |
| EPS Diluted | -0.29 | -0.80 | -0.35 | -0.63 | -0.62 |
| Normalized Diluted EPS | -0.18 | -0.29 | -0.22 | -0.31 | -0.39 |
| Average Basic Shares Outstanding | 6.59M | 6.02M | 5.46M | 3.95M | 1.78M |
| Average Diluted Shares Outstanding | 6.59M | 6.02M | 5.46M | 3.95M | 1.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |